Valeant

Pershing Square Capital Management, a major investment holding company managed by billionaire Bill Ackman, released on Wednesday its quarterly letter to investors. Net of all fees, the fund returned 2.9 percent in the third quarter and is lower by 13.5 percent since the start of 2016. By comparison...

Federal prosecutors in the state of New York charged former Valeant Pharmaceuticals Intl Inc (NYSE: VRX) executive Gary Tanner for alleged colluding with Andrew Davenport, who was Philidor Rx's CEO. It was further alleged that $40 million was routed toward Davenport through various entities, and...

It is no secret that Valeant Pharmaceuticals Intl Inc (NYSE: VRX) needs to divest some of its assets to give the company sufficient liquidity to reduce its debt load before it becomes potentially unmanageable. The Wall Street Journal reported in early November that the pharmaceutical company has...

Gary Nachman of BMO Capital Markets has some good news and bad news for Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s investors following the company's third-quarter earnings report. The good news is that Valeant's new segment reporting could provide greater visibility on its business outlook. The...

Voting for the U.S. presidential election is underway and one group of investors couldn't be more relieved that the end is in sight. As noted by Gadfly's Max Nisen, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) has fallen 23 percent year-to-date while the Bloomberg...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) stock has tumbled more than 30 percent and hit a new 52-week low of $13.77 before recovering above the $15 per share level. Investors and traders dumped Valeant's stock after the company's third quarter earnings report fell short of Wall...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is reportedly shopping for buyers to acquire its Salix unit for an expected $8.5 billion and additional royalty payments in the future. Valeant is plagued with debt, causing some concern among shareholders so any cash infusion would certainly ease...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) soared Tuesday after The Wall Street Journal reported the company is in talks to sell its Salix unit for up to $10 billion. Salix, a leader in the gastrointestinal market, was acquired by Valeant back in February 2015 for $158 per share,...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) have plunged roughly 90 percent over the past year and the company's mounting debt load is having investors think the company's only path towards long-term survival is selling off core assets. Billionaire hedge fund manager and...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) hit a new 52-week low of $22.52 on Tuesday after the company released an investor presentation in conjunction with its first quarter results and conference call. Valeant earned $1.27 per share in the first quarter on revenue of $2.4 billion...

Earnings highlights this week include results from a recently merged semiconductor producer. A leading medical technology company is also set to share its latest quarterly results this week. Wall Street analysts are looking for solid bottom-line growth from each of them. In what overall will be a...

The Wall Street Journal reported late Thursday afternoon that prior to hiring Joseph Papa as CEO, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) received an acquisition proposal from Japan's Takeda Pharmaceutical and private equity firm TPG. The Wall Street Journal, citing "people familiar with the...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has become one of the most talked about companies on Wall Street given its policy of drug pricing. Activist investor, major Valeant shareholder and board member was a guest on CNBC to discuss the companies past, present and future. Ackman was asked...